Previous 10 | Next 10 |
ASLAN Pharmaceuticals (NASDAQ: ASLN ): Q3 GAAP EPS of -$0.03 beats by $0.20 . More news on: ASLAN Pharmaceuticals Limited, Earnings news and commentary, Healthcare stocks news, , Read more ...
SINGAPORE, Oct. 31, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today reported financial results for the quarter ended 30 September 2019 and provided an update on its clinical activities. Dr...
The first participant has been enrolled in a Phase 1 proof-of-concept clinical trial evaluating multiple ascending doses of ASLAN Pharmaceuticals' ( ASLN +1.9% ) ASLAN004 in patients with moderate-to-severe atopic dermatitis. The 50-subject study should wind up in about a year. More ...
- Multiple ascending dose study will assess the safety and efficacy of ASLAN004 in patients with moderate to severe atopic dermatitis - ASLAN004 has previously demonstrated a favourable tolerability profile, complete inhibition of downstream mediators and potential for once monthly do...
SINGAPORE, Oct. 18, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced it has secured a US$3 million loan facility provided by the company’s chairman, members of the bo...
SINGAPORE, Oct. 02, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced the presentation of new data from a phase 1b open-label, dose escalation study of varlitinib in combi...
- ASLAN spins out pre-clinical assets in joint venture with Bukwang to form JAGUAHR Therapeutics with Bukwang investing up to US$5 million - ASLAN and Bukwang will co-own new entity to develop novel pre-clinical AhR antagonists SINGAPORE and SEOUL, Sept. 30, 2019 (GLOBE NEWSWI...
- Biliary tract cancer (BTC) patients treated with varlitinib plus capecitabine in second line achieved a response rate of 11% including two complete responses, median PFS of 2.7 months and OS of 5.8 months - Patients on study appeared to present with more aggressive diseas...
Gainers : Fibrocell Science (NASDAQ: FCSC ) +60% . Mer Telemanagement Solutions (NASDAQ: MTSL ) +40% . Francesca's Holdings Corporation (NASDAQ: FRAN ) +30% . OpGen (NASDAQ: OPGN ) +26% . Vince Holding (NYSE: VNCE ) +24% . ASLAN Pharmaceuticals Limited (NASDAQ: ASLN ) +22% . Medallia...
SINGAPORE, Sept. 10, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that an abstract on its lead candidate, varlitinib, has been accepted for poster presentation at the ...
News, Short Squeeze, Breakout and More Instantly...
ASLAN Pharmaceuticals Limited Company Name:
ASLN Stock Symbol:
NASDAQ Market:
Positive interim data readout from 22 patients in TREK-DX study of eblasakimab showed unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of dupilumab -experienced AD patients treated with 400mg eblasakimab weekly ...
New positive data from an additional analysis of dupilumab-experienced patients treated with eblasakimab 400mg, weekly over 16 weeks further supp...